In contrast, a 54-week trial of liraglutide did not show significant motor improvement (MDS-UPDRS III), but daily living activities (MDS-UPDRS II) improved significantly, suggesting functional gains without direct motor benefit [57]
GIP/GLP-1 dual agonists such as tirzepatide additionally engage the GIP receptor, layering in a second incretin mechanism
The decision to continue, modify, or discontinue semaglutide should be individualized, weighing the cardiovascular and metabolic benefits of the medication against the impact of gastrointestinal side effects on patient well-being and treatment adherence
Conclusion Step count was identified through qualitative research and confirmed by subject matter experts and regulators as a promising DHT-based feature for use in the CHF population
Let me tell you about Sarah (not her real name, but this story plays out in my office all the time)
There are 50 servings per container